143 related articles for article (PubMed ID: 30105541)
1. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY
Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Kang JH; Lee SH; Lee JS; Oh SJ; Ha JS; Choi HJ; Kim SY
Cells; 2020 Jun; 9(6):. PubMed ID: 32560270
[TBL] [Abstract][Full Text] [Related]
6. A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
Kim SY; Keillor JW
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260198
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2-Mediated p53 Depletion Promotes Angiogenesis by Increasing HIF-1α-p300 Binding in Renal Cell Carcinoma.
Lee SH; Kang JH; Ha JS; Lee JS; Oh SJ; Choi HJ; Song J; Kim SY
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708896
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of transglutaminase 2 drives glycolytic metabolism in renal carcinoma cells.
Ku BM; Lee CH; Lee SH; Kim SY
Amino Acids; 2014 Jun; 46(6):1527-36. PubMed ID: 24643363
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition.
Jeong KC; Ahn KO; Lee BI; Lee CH; Kim SY
J Cancer Res Clin Oncol; 2010 Jan; 136(1):143-50. PubMed ID: 19655169
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel target for renal cell carcinoma: transglutaminase 2.
Kang JH; Lee SH; Kim SY
Cell Death Dis; 2016 Apr; 7(4):e2200. PubMed ID: 27100894
[No Abstract] [Full Text] [Related]
11. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
[TBL] [Abstract][Full Text] [Related]
12. New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds.
Kim SY
Med Sci (Basel); 2018 Oct; 6(4):. PubMed ID: 30297644
[TBL] [Abstract][Full Text] [Related]
13. GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3).
Hitomi K; Ikura K; Maki M
Biosci Biotechnol Biochem; 2000 Mar; 64(3):657-9. PubMed ID: 10803976
[TBL] [Abstract][Full Text] [Related]
14. Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition.
Lee SH; Lee WK; Kim N; Kang JH; Kim KH; Kim SG; Lee JS; Lee S; Lee J; Joo J; Kwon WS; Rha SY; Kim SY
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30463244
[TBL] [Abstract][Full Text] [Related]
15. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
Kim DS; Park SS; Nam BH; Kim IH; Kim SY
Cancer Res; 2006 Nov; 66(22):10936-43. PubMed ID: 17108131
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
[TBL] [Abstract][Full Text] [Related]
17. Inter-molecular crosslinking activity is engendered by the dimeric form of transglutaminase 2.
Kim N; Lee WK; Lee SH; Jin KS; Kim KH; Lee Y; Song M; Kim SY
Amino Acids; 2017 Mar; 49(3):461-471. PubMed ID: 27394142
[TBL] [Abstract][Full Text] [Related]
18. Tissue transglutaminase-induced down-regulation of matrix metalloproteinase-9.
Ahn JS; Kim MK; Hahn JH; Park JH; Park KH; Cho BR; Park SB; Kim DJ
Biochem Biophys Res Commun; 2008 Nov; 376(4):743-7. PubMed ID: 18809380
[TBL] [Abstract][Full Text] [Related]
19. Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors.
Kim N; Kwak SH; Lee SH; Juvekar V; Lee BI; Ahn HC; Kim SY; Gong YD
Org Biomol Chem; 2014 Jul; 12(27):4932-40. PubMed ID: 24879506
[TBL] [Abstract][Full Text] [Related]
20. Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase.
Lai TS; Hausladen A; Slaughter TF; Eu JP; Stamler JS; Greenberg CS
Biochemistry; 2001 Apr; 40(16):4904-10. PubMed ID: 11305905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]